2,3-bis(3'-hydroxybenzyl)butyrolactone has been researched along with phosphotyrosine in 1 studies
| Studies (2,3-bis(3'-hydroxybenzyl)butyrolactone) | Trials (2,3-bis(3'-hydroxybenzyl)butyrolactone) | Recent Studies (post-2010) (2,3-bis(3'-hydroxybenzyl)butyrolactone) | Studies (phosphotyrosine) | Trials (phosphotyrosine) | Recent Studies (post-2010) (phosphotyrosine) |
|---|---|---|---|---|---|
| 319 | 32 | 124 | 6,475 | 4 | 751 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, LH; Demark-Wahnefried, W; Fang, J; Li, H; Lin, X; Sun, Z; Wu, Y | 1 |
1 other study(ies) available for 2,3-bis(3'-hydroxybenzyl)butyrolactone and phosphotyrosine
| Article | Year |
|---|---|
Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.
Topics: 4-Butyrolactone; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Lignans; Male; Phosphotyrosine; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction | 2009 |